Search results for "SUBGROUPS"
showing 10 items of 34 documents
An observational study of patient satisfaction with fesoterodine in the treatment of overactive bladder: effects of additional educational material
2014
Summary Aim To compare the effects of additional educational material on treatment satisfaction of overactive bladder (OAB) patients treated with a muscarinic receptor antagonist. Methods In an observational study of OAB patients being treated by their physician with fesoterodine for 4 months (FAKTEN study), sites were randomised to providing standard treatment or additional educational material including the SAGA tool. Patient satisfaction was assessed by three validated patient-reported outcomes including the Treatment Satisfaction Question. Because of premature discontinuation of the study, descriptive statistical analysis was performed. Results A total of 431 and 342 patients received s…
An answer to a question of Isaacs on character degree graphs
2006
Abstract Let N be a normal subgroup of a finite group G. We consider the graph Γ ( G | N ) whose vertices are the prime divisors of the degrees of the irreducible characters of G whose kernel does not contain N and two vertices are joined by an edge if the product of the two primes divides the degree of some of the characters of G whose kernel does not contain N. We prove that if Γ ( G | N ) is disconnected then G / N is solvable. This proves a strong form of a conjecture of Isaacs.
On the product of a π-group and a π-decomposable group
2007
[EN] The main result in the paper states the following: Let π be a set of odd primes. Let the finite group G=AB be the product of a π -decomposable subgroup A=Oπ(A)×Oπ′(A) and a π -subgroup B . Then Oπ(A)⩽Oπ(G); equivalently the group G possesses Hall π -subgroups. In this case Oπ(A)B is a Hall π-subgroup of G. This result extends previous results of Berkovich (1966), Rowley (1977), Arad and Chillag (1981) and Kazarin (1980) where stronger hypotheses on the factors A and B of the group G were being considered. The results under consideration in the paper provide in particular criteria for the existence of non-trivial soluble normal subgroups for a factorized group G.
On finite groups generated by strongly cosubnormal subgroups
2003
[EN] Two subgroups A and B of a group G are cosubnormal if A and B are subnormal in their join and are strongly cosubnormal if every subgroup of A is cosubnormal with every subgroup of B. We find necessary and sufficient conditions for A and B to be strongly cosubnormal in and, if Z is the hypercentre of G=, we show that A and B are strongly cosubnormal if and only if G/Z is the direct product of AZ/Z and BZ/Z. We also show that projectors and residuals for certain formations can easily be constructed in such a group. Two subgroups A and B of a group G are N-connected if every cyclic subgroup of A is cosubnormal with every cyclic subgroup of B (N denotes the class of nilpotent groups). Thou…
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
2021
PETHEMA/GEM Cooperative Group.
Sylow permutable subnormal subgroups of finite groups II
2001
[EN] In this paper a local version of Agrawal's theorem about the structure of finite groups in which Sylow permutability is transitive is given. The result is used to obtain new characterisations of this class of finite groups.
A classification of C-Fuchsian subgroups of Picard modular groups
2017
Survival and quality of life after early discharge in low-risk pulmonary embolism.
2020
IntroductionEarly discharge of patients with acute low-risk pulmonary embolism requires validation by prospective trials with clinical and quality-of-life outcomes.MethodsThe multinational Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE) single-arm management trial investigated early discharge followed by ambulatory treatment with rivaroxaban. The study was stopped for efficacy after the positive results of the predefined interim analysis at 50% of the planned population. The present analysis includes the entire trial population (576 patients). In addition to 3-month recurrence (primary outcome) and 1-year overall mortality, …
Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de …
2021
Different primary and secondary prevention studies have documented that a greater degree of reduction in low-density lipoprotein cholesterol (LDL-C) levels is associated with a greater decrease in cardiovascular event rates. PCSK9 inhibitors achieve important, rapid and sustained decreases in LDL-C. New clinical practice guidelines for the management of dyslipidemia establish reduced target levels of LDL-C. These goals are hardly achievable with a statin-only treatment, even in combination with ezetimibe. The addition of PCSK9 inhibitors can play a determining role in achieving these recommendations. However, it is important to identify the patient subgroups that can most benefit from this …